Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press77510.17650/1994-4098-2020-16-4-35-40MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИThe role of biomarkers in the early diagnostics of breast cancerРоль биомаркеров в ранней диагностике рака молочной железыIsmagilovA. Kh.ИсмагиловА. Х.
Russian Federation

29 Sibirskiy trakt, Kazan 420029

29 Sibirskiy trakt, Kazan 420029

420029 Казань, Сибирский тракт, 29 

420029 Казань, Сибирский тракт, 29

https://orcid.org/0000-0002-0993-0138KhuzinaD. R.ХузинаД. Р.
Russian Federation

29 Sibirskiy trakt, Kazan 420029

420029 Казань, Сибирский тракт, 29

https://orcid.org/0000-0002-2347-3535VanesyanA. S.ВанесянА. С.
Spain

71 Josep Vicens Foix St., Barcelona 08034

Анна Спартаковна Ванесян 

08034 Барселона, ул. Джозеп Виченц Фуа, 71 

anna_vanesyan@yahoo.comZaystevaV. V.ЗайцеваВ. В.
Russian Federation

29 Sibirskiy trakt, Kazan 420029

420029 Казань, Сибирский тракт, 29

Kazan State Medical Academy – branch of Federal State Budgetary Educational Institution of Higher Professional Education of Russian Medical Academy of Postgraduate Education of Ministry of Healthcare RussiaКазанская государственная медицинская академия – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииTatarstan Regional Clinical Cancer CenterГАУЗ «Республиканский клинический онкологический диспансер» Министерства здравоохранения Республики ТатарстанClinic “Creu Blanca”Клиника «Креу Бланка»13122020164354012032021120320212020https://ojrs.abvpress.ru/ojrs/article/view/775

One of the main priorities in modern oncology is the identification and clinical application of biomarkers that can be helpful in the diagnostics and prognostication of cancer. The aim of this article was to review biomarkers for early diagnosis and prediction of prognosis of breast cancer. There were reviewed three main groups of biomarkers in this article: familial breast cancer biomarkers with high and low penetration (BRCA1, BRCA2, TP53, etc.), biomarkers of breast cancer molecular subtypes (luminal A and luminal B, HER2/neu, basal and low in claudine) and biomarkers of early stage breast cancer progression (multigenic panels).

Одним из приоритетных направлений в современной онкологии является выявление и клиническое применение биомаркеров, которые помогают при ранней диагностике рака или прогнозируют скорость его прогрессирования. Целью данной статьи являлся обзор биомаркеров для диагностики и прогнозирования прогрессирования рака молочной железы на ранних стадиях. В статье изучены 3 основные группы биомаркеров: биомаркеры наследственного рака молочной железы с высокой и низкой пенетрантностью (BRCA1, BRCA2, TP53 и т. д.), биомаркеры молекулярных подтипов рака молочной железы (люминальные А и В подтипы, с гиперэкспрессией HER2, базальный и с низким содержанием клаудина) и прогностические биомаркеры (мультигенные панели) рака молочной железы ранних стадий.

breast cancerbiomarkersmolecular subtypesearly stage breast cancer prognosticationрак молочной железыбиомаркерымолекулярные подтипыпрогнозирование рака ранних стадийGBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study. Lancet 2016;388(10053):1659–724. DOI: 10.1016/S0140-6736(16)31679-8.GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study. Lancet 2016;388(10053):1659–724. DOI: 10.1016/S0140-6736(16)31679-8.Hinestrosa M.C., Dickersin K., Klein P. et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer 2007;7(4):309–15. DOI: 10.1038/nrc2113.Hinestrosa M.C., Dickersin K., Klein P. et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer 2007;7(4):309–15. DOI: 10.1038/nrc2113.Gang L., Jing H., Guohong H. Biomarker studies in early detection and prognosis of breast cancer. AEMB 2017;1026:27–39. DOI: 10.1007/978-981-10-6020-5_2.Gang L., Jing H., Guohong H. Biomarker studies in early detection and prognosis of breast cancer. AEMB 2017;1026:27–39. DOI: 10.1007/978-981-10-6020-5_2.Gershtein E.S., Kushlinskiy N.E. Breast Cancer biological markers: methodological aspects and clinical recommendations. Mammologiya = Mammology;(1):65–9. (In Russ.).Герштейн Е.С., Кушлинский Н.Е. Биологические маркеры рака молочной железы: методологические аспекты и клинические рекомендации. Маммология 2005;(1):65–9.Lynch H.T., Krush A.J. Carcinoma of the breast and ovary in three families. Surg Gynecol Obstet 1971;133(4):644–8. DOI: 10.1097/00006254-197203000-00014.Lynch H.T., Krush A.J. Carcinoma of the breast and ovary in three families. Surg Gynecol Obstet 1971;133(4):644–8. DOI: 10.1097/00006254-197203000-00014.Hall J.M., Lee M.K., Newman B. et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250(4988):1684–89. DOI: 10.1126/science.2270482.Ford D., Easton D.F., Stratton M. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62(3):676–89. DOI: 10.1086/301749.Ford D., Easton D.F., Stratton M. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62(3):676–89. DOI: 10.1086/301749.Lord C.J., Ashworth A. BRCAness revisited. Nat Rev Cancer 2016;16(2): 110–20. DOI: 10.1038/nrc.2015.21.Turner N., Tutt A., Ashworth A. Hallmarks of ”BRCAness” in sporadic cancers. Nat Rev Cancer 2004;4(10):814–9. DOI: 10.1038/nrc1457.Turner N., Tutt A., Ashworth A. Hallmarks of ”BRCAness” in sporadic cancers. Nat Rev Cancer 2004;4(10):814–9. DOI: 10.1038/nrc1457.Prakash R., Zhang Y., Feng W., Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol 2015;7:4. DOI: 10.1101/cshperspect.a016600.Prakash R., Zhang Y., Feng W., Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol 2015;7:4. DOI: 10.1101/cshperspect.a016600.Gulyan I.S., Chernysheva N.Yu., Stenkova A.M. et al. Breast cancer: risk-associated mutations of BRCA gene in the habitants of Primorskiy region. Tomskiy meditsinskiy zhurnal = Tomsk Medical Journal 2018;1:44–7. (In Russ.). DOI: 10.17238/PmJ1609-1175.2018.1.44-47.Гулян И.С., Чернышева Н.Ю., Стенкова А.М. и др. Рак молочной железы: риск-ассоциированные мутации гена BRCA1 для скрининга жителей Приморья. Томский медицинский журнал 2018;(1):44–7. DOI: 10.17238/PmJ1609-1175.2018.1.44-47.Zikiryakhodzhaev A.D., Frolova M.A., Rasskazova E.A., Glazkova E.V. Treatment of triple negative subtype of breast cancer. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system 2017;13(2):20–6. (In Russ.). DOI: 10.17650/1994-4098-2017-13-2-20-26.Зикиряходжаев А.Д., Фролова М.А., Рассказова Е.А., Глазкова Е.В, Лечение тройного негативного подтипа рака молочной железы. Опухоли женской репродуктивной системы 2017;13(2): 20–6. DOI: 10.17650/1994-4098-2017-13-2-20-26.Anokhina E.N. Polymorphism of the pro- and antiinflammatory cytokines, mutations in the gens BRCA1/2 in cancers of female reproductive system. Summary of thesis … of candidate of medical sciences. Maykop, 2015. 25p. (In Russ.).Анохина Е.Н. Полиморфизмы генов про- и противовоспалительных цитокинов, мутации генов BRCA1/2 при злокачественных новообразованиях органов женской репродуктивной системы. Автореф. дис. … канд. мед. наук. Майкоп, 2015. 25 с.Bit-Sava E.M. Molecular-genetic basis of the treatment of BRCA1/СНЕК2/BLM associated and sporadic breast cancer. Summary of thesis … of candidate of medical sciences. Saint Petersburg, 2014. 48 p. (In Russ.).Бит-Сава Е.М. Молекулярно-биологическое обоснование лечения BRCA1/ СНЕК2/BLM-ассоциированного и спорадического рака молочной железы. Aвтореф. дис. … д-ра мед. наук. СПб., 2014. 48 с.Hisada M., Garber J.E., Fung C.Y. et al. Multiple primary cancers in families with li Fraumeni syndrome. J Natl Cancer Inst 1998;90(8):606–11. DOI: 10.5301/ jbm.5000227.Hisada M., Garber J.E., Fung C.Y. et al. Multiple primary cancers in families with li Fraumeni syndrome. J Natl Cancer Inst 1998;90(8):606–11. DOI: 10.5301/ jbm.5000227.Kaurah P., MacMillan A., Boyd N. et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007;297(21):2360–72. DOI: 10.1001/jama.297.21.2360.Kaurah P., MacMillan A., Boyd N. et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007;297(21):2360–72. DOI: 10.1001/jama.297.21.2360.Marsh D.J., Kum J.B., Lunetta K.L. et al. PTEN mutation spectrum and genotypephenotype correlations in BannayanRiley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999;8(8):1461–72. DOI: 10.1093/hmg/8.8.1461.Marsh D.J., Kum J.B., Lunetta K.L. et al. PTEN mutation spectrum and genotypephenotype correlations in BannayanRiley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999;8(8):1461–72. DOI: 10.1093/hmg/8.8.1461.Thompson D., Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004;9(3):221–36. DOI: 10.1023/ B:JOMG.0000048770.90334.3b.Thompson D., Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004;9(3):221–36. DOI: 10.1023/ B:JOMG.0000048770.90334.3b.Erkko H., Xia B., Nikkila J. et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007;446(7133):316–9.Erkko H., Xia B., Nikkila J. et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007;446(7133):316–9.Thompson D., Duedal S., Kirner J. et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005;97(11):813–22. DOI: 10.1023/B:JOMG.0000048770.90334.3b.Thompson D., Duedal S., Kirner J. et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005;97(11):813–22. DOI: 10.1023/B:JOMG.0000048770.90334.3b.Seal S., Thompson D., Renwick A. Truncating mutations in the Fanconi anemia J gene BRIP1 are low penetrance breast cancer susceptibility alleles. Nat Genet 2006;38(11):1239–41. DOI: 10.1038/ng1902.Seal S., Thompson D., Renwick A. Truncating mutations in the Fanconi anemia J gene BRIP1 are low penetrance breast cancer susceptibility alleles. Nat Genet 2006;38(11):1239–41. DOI: 10.1038/ng1902.Savitsky K., Bar-Shira A., Gilad S. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268(5218):1749–53. DOI: 10.1126/science.7792600.Savitsky K., Bar-Shira A., Gilad S. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268(5218):1749–53. DOI: 10.1126/science.7792600.Kovalenko S.P. Hereditary and somatic mutations as molecular markers for the diagnostics and treatment of breast cancer. Summary of thesis … of candidate of biological sciences. Novosibirsk, 2014. 35 p. (In Russ.).Коваленко С.П. Наследственные и соматические мутации как молекулярные маркеры для диагностики и лечения рака молочной железы. Aвтореф. дис. … д-ра биол. наук. Новосибирск, 2014. 35 с.Grishina K.A., Muzaffarova T.A., Khaylenko V.A., Karpukhin A.V. Molecular-genetic markers of the breast cancer. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system 2016;12(3):36–42. (In Russ.). DOI: 10.17650/1994-4098-2016-12-3-36-42.Гришина К.А., Музаффарова Т.А., Хайленко В.А., Карпухин А.В. Молекулярно-генетические маркеры рака молочной железы. Опухоли женской репродуктивной системы 2016;12(3): 36–42 DOI: 10.17650/1994-4098-2016-12-3-36-42.Laptiev S.A., Korzhenevskaya M.A., Imyanitov E.N. The molecular-gentic “portrait” of breast cancer. Uchenye zapiske SPBGMU im. I.P. Pavlova = Scientific Notes of Saint-Petersburg Medical University 201724(2):12–22. (In Russ.). DOI: 10.24884/1607-41812017-24-2-12-22.Лаптиев С.А., Корженевская М.А., Имянитов Е.Н. Молекулярно-генетический “портрет” рака молочной железы. Ученые записки СПбГМУ им. И.П. Павлова 2017;24(2):12–22.. DOI: 10.24884/1607-41812017-24-2-12-22.Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011;378(9805):1812–23. DOI: 10.1016/s0140-6736(11)61539-0.Caldas C., Aparicio S.A. The molecular outlook. Nature 2002;415:484–5. DOI: 10.1038/415484a.Caldas C., Aparicio S.A. The molecular outlook. Nature 2002;415:484–5. DOI: 10.1038/415484a.Lonning P.E. Poor-prognosis estrogen receptor positive disease: present and future clinical solutions. Ther Adv Med Oncol 2012;4(3):127–37. DOI: 10.1177/1758834012439338.Lonning P.E. Poor-prognosis estrogen receptor positive disease: present and future clinical solutions. Ther Adv Med Oncol 2012;4(3):127–37. DOI: 10.1177/1758834012439338.Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple negative breast cancer. N Engl J Med 2010;363(20):1938–48. DOI: 10.1056/NEJMra1001389.Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple negative breast cancer. N Engl J Med 2010;363(20):1938–48. DOI: 10.1056/NEJMra1001389.Gens G., Moiseeva N.I., Ovsiy O.G. The problems of individualization of medical treatment in breast cancer patients. Vestnik RNCRR 2014;(1):4. (In Russ.).Генс Г.П., Моисеева Н.И., Овсий О.Г. Проблемы индивидуализации лекарственного лечения у больных раком молочной железы. Вестник РНЦРР 2014;(1):4.Sabatier R., Finetti P., Guille A. Claudinlow breast cancers: clinical, pathological, molecular and prognostic characterization. Mol Cancer 2014;13:228. DOI: 10.1371/journal.pone.0168669.Sabatier R., Finetti P., Guille A. Claudinlow breast cancers: clinical, pathological, molecular and prognostic characterization. Mol Cancer 2014;13:228. DOI: 10.1371/journal.pone.0168669.Harris L., Fritsche H., Mennel R. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287–312. DOI: 10.1200/JCO.2007.14.2364.Harris L., Fritsche H., Mennel R. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287–312. DOI: 10.1200/JCO.2007.14.2364.Kyle R.A., Yee G.C., Somerfield M.R. et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25(17):2464–72. DOI: 10.1200/JCO.2007.12.1269.Kyle R.A., Yee G.C., Somerfield M.R. et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25(17):2464–72. DOI: 10.1200/JCO.2007.12.1269.